Akebia Therapeutics, Inc. (AKBA) Estados Financieros e Histórico

Akebia Therapeutics, Inc. (AKBA) — Precio $0.92 HealthcareBiotechnology — NASDAQ

Últimos resultados publicados:

Estados financieros detallados de Akebia Therapeutics, Inc. (AKBA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.

Resumen del Análisis

Akebia Therapeutics, Inc. registró ingresos de $236.2M en el último ejercicio fiscal, con un CAGR de 5 años del -4.3%.

Márgenes de los últimos 12 meses: margen bruto 79.5%, margen operativo -6.9%, margen neto -13.5%.

Al precio actual de $0.92, AKBA presenta beneficios negativos (P/E no significativo) y un ROE del -93.74%. La capitalización bursátil es de $246M.

Cuenta de Resultados (10 años)

Año2016201720182019202020212022202320242025
Ingresos$1.5M$178.0M$207.7M$335.0M$294.6M$211.7M$292.5M$194.6M$160.2M$236.2M
Coste de Ventas$115.8M$617000$7.7M$145.3M$64.0M$81.5M$22.5M$74.1M$63.2M$39.5M
Beneficio Bruto-$114.2M$177.4M$200.1M$189.7M$230.7M$130.2M$270.0M$120.5M$97.0M$196.7M
I+D$115.8M$230.9M$291.1M$323.0M$218.5M$147.9M$166.0M$63.1M$37.7M$62.4M
Generales y Administrativos$22.2M$27.0M$87.1M$149.5M$154.1M$174.1M$138.6M$100.2M$106.5M$107.5M
Gastos Operativos$138.0M$257.9M$378.2M$476.0M$608.5M$394.7M$350.8M$166.7M$147.5M$173.2M
Beneficio Operativo-$136.5M-$79.9M-$178.1M-$286.3M-$377.8M-$264.5M-$80.8M-$46.3M-$50.5M$23.5M
EBITDA-$136.2M-$76.1M-$178.1M-$249.9M-$139.8M-$189.9M$3.1M-$8.3M-$13.7M$21.7M
Gastos por Intereses000$1.4M$8.9M$19.9M$15.7M$6.0M$18.2M$24.2M
Beneficio Antes de Impuestos-$135.7M-$76.9M-$171.9M-$286.3M-$384.8M-$282.0M-$94.2M-$51.9M-$69.4M-$3.7M
Impuestos-$901000-$2.8M-$28.3M-$6.6M00000$1.6M
Beneficio Neto-$135.7M-$76.9M-$171.9M-$279.7M-$384.8M-$282.0M-$94.2M-$51.9M-$69.4M-$5.3M
BPA$-3.60$-1.77$-1.47$-2.36$-2.53$-1.48$-0.58$-0.28$-0.33$-0.02
BPA Diluido$-3.60$-1.77$-1.47$-2.36$-2.53$-1.48$-0.58$-0.28$-0.33$-0.02
Acciones en Circulación (Diluidas)$37.7M$43.5M$116.9M$118.4M$138.5M$165.9M$182.8M$187.5M$210.9M$257.2M

Cuenta de Resultados (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Ingresos$58.8M$57.6M$53.5M$49.1M
Beneficio Bruto$49.1M$45.4M$40.9M$38.7M
Beneficio Operativo$4.4M-$8.6M-$4.7M-$6.3M
EBITDA$6.2M-$6.1M-$13.3M-$4.9M
Beneficio Neto$540000-$12.2M-$9.1M-$8.9M
BPA$0.00$-0.05$-0.03$-0.03
BPA Diluido$0.00$-0.05$-0.03$-0.03

Balance (10 años)

Año2016201720182019202020212022202320242025
Caja y Equivalentes$187.3M$70.2M$104.6M$147.7M$229.1M$149.8M$90.5M$42.9M$51.9M$184.8M
Inversiones a Corto$73.0M$247.6M$217.0M$245000$40.0M00000
Cuentas por Cobrar$33.8M$34.2M$16.7M$38.9M$28.6M$51.6M$40.3M$39.3M$34.4M$47.0M
Inventario00$114.2M$116.3M$61.0M$36.6M$21.6M$15.7M$16.2M$15.6M
Activos Corrientes$296.3M$358.4M$468.3M$309.5M$371.4M$271.1M$185.2M$118.1M$113.8M$184.8M
Inmovilizado Material$2.6M$3.6M$8.0M$39.4M$35.5M$40.6M$34.4M$16.0M$10.4M0
Fondo de Comercio00$55.1M$55.1M$55.1M$59.0M$59.0M$59.0M$59.0M$59.0M
Activos Intangibles00$328.2M$291.2M$144.2M$108.1M$72.1M$36.0M00
Activos Totales$300.2M$364.2M$996.5M$771.2M$644.1M$529.3M$356.1M$241.7M$220.7M$376.6M
Cuentas por Pagar$2.0M$7.0M$42.8M$39.2M$41.3M$33.6M$18.0M$14.6M$15.2M$21.2M
Deuda a Corto00$15.0M$5.0M$5.3M$97.5M$32.0M$19.5M$4.3M$40.1M
Pasivos Corrientes$114.3M$144.3M$265.7M$208.1M$187.1M$261.1M$129.5M$99.9M$80.9M$162.9M
Deuda a Largo000$75.8M$96.4M$53.1M$34.1M$71.2M$175.5M$176.2M
Pasivos Totales$232.1M$244.9M$360.6M$376.4M$396.5M$455.3M$350.8M$272.3M$269.9M$344.0M
Reservas-$297.1M-$374.1M-$514.4M-$794.1M-$1.18B-$1.46B-$1.56B-$1.61B-$1.68B-$1.68B
Patrimonio Neto$68.1M$119.3M$635.9M$394.8M$247.6M$74.0M$5.2M-$30.6M-$49.2M$32.6M
Deuda Total00$15.0M$108.3M$126.3M$189.1M$99.8M$104.2M$188.7M$216.3M
Deuda Neta-$260.3M-$317.8M-$306.6M-$39.6M-$142.8M$39.3M$9.3M$61.3M$136.9M$31.5M
Capital Circulante$182.1M$214.0M$202.6M$101.4M$184.3M$10.1M$55.6M$18.3M$32.9M$21.9M

Balance (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Caja y Equivalentes$166.4M$184.8M$162.6M$155.5M
Activos Totales$364.2M$376.6M$362.5M$349.7M
Pasivos Totales$322.6M$344.0M$335.1M$324.6M
Patrimonio Neto$41.6M$32.6M$27.4M$25.0M
Deuda Total$52.6M$51.8M$12.5M$54.0M

Flujo de Caja (10 años)

Año2016201720182019202020212022202320242025
Beneficio Neto-$135.7M-$76.9M-$143.6M-$279.7M-$383.5M-$282.0M-$92.6M-$51.9M-$69.4M-$5.3M
Amortizaciones$296000$617000$2.4M$38.6M$33.6M$38.0M$37.7M$41.8M$37.5M$1.3M
Compensación en Acciones$5.8M$8.9M$19.0M$11.9M$24.5M$22.7M$17.8M$9.3M$7.8M$11.3M
Cambio en Capital Circulante$186.7M$7.2M$36.0M-$99.1M-$13.7M-$105.6M-$1.4M-$20.7M-$39.7M$16.5M
Flujo de Caja Operativo$57.9M-$56.2M-$97.5M-$257.4M-$110.4M-$253.0M-$73.2M-$23.4M-$40.7M$68.0M
Inversiones (CapEx)-$2.7M-$1.6M-$1.6M-$6.7M-$317000-$59000-$1140000-$33000-$291000
Adquisiciones$2.7M$1.6M$6.1M0$39.7M00000
Recompra de Acciones000-$4260000000-$1.3M0
Dividendos Pagados0000000000
Flujo de Caja Libre$55.2M-$57.8M-$99.1M-$264.1M-$110.7M-$253.0M-$73.3M-$23.4M-$40.7M$68.0M

Flujo de Caja (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Flujo de Caja Operativo$28.1M$31.1M-$21.2M$3.5M
Inversiones (CapEx)-$77000-$162000-$62000-$1.1M
Flujo de Caja Libre$28.0M$31.0M-$21.2M$2.4M
Dividendos Pagados0000
Compensación en Acciones$3.2M$3.2M$3.7M$3.2M

Crecimiento y Márgenes (10 años)

Año2016201720182019202020212022202320242025
Crecimiento Ingresos (anual)+11495.0%+16.7%+61.3%-12.0%-28.2%+38.2%-33.5%-17.7%+47.5%
Crecimiento Beneficio Neto (anual)+43.3%-123.5%-62.7%-37.6%+26.7%+66.6%+44.9%-33.7%+92.3%
Crecimiento BPA (anual)+50.8%+16.9%-60.5%-7.2%+41.5%+60.8%+51.7%-17.9%+93.7%
Cambio en Acciones (anual)+15.3%+168.7%+1.3%+16.9%+19.9%+10.1%+2.6%+12.5%+21.9%
Crecimiento FCF (anual)-204.6%-71.5%-166.5%+58.1%-128.6%+71.0%+68.1%-74.0%+267.1%
Margen Bruto-7443.0%99.7%96.3%56.6%78.3%61.5%92.3%61.9%60.6%83.3%
Margen Operativo-8889.9%-44.9%-85.8%-85.5%-128.2%-125.0%-27.6%-23.8%-31.5%9.9%
Margen EBITDA-8870.6%-42.7%-85.7%-74.6%-47.5%-89.7%1.0%-4.2%-8.6%9.2%
Margen Neto-8843.5%-43.2%-82.7%-83.5%-130.6%-133.3%-32.2%-26.7%-43.3%-2.3%
Margen FCF3599.0%-32.5%-47.7%-78.8%-37.6%-119.5%-25.1%-12.0%-25.4%28.8%
Tasa Impositiva Efectiva0.7%3.6%16.5%2.3%-0.0%-0.0%-0.0%-0.0%-0.0%-43.6%

Datos por Acción (10 años)

Año2016201720182019202020212022202320242025
FCF por Acción$1.46$-1.33$-0.85$-2.23$-0.80$-1.52$-0.40$-0.12$-0.19$0.26
Dividendo por Acción$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Acciones en Circulación (Básicas)$37.7M$43.5M$116.9M$118.4M$138.5M$165.9M$182.8M$187.5M$210.9M$257.2M

Qué mirar en Biotech

La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.

Rentabilidad

Rentabilidad sobre capital-93.74%
Rentabilidad sobre capital invertido-7.08%
Rentabilidad sobre activos-8.48%
Margen bruto79.48%
Margen operativo-6.91%
Margen neto-13.54%

Salud financiera

Deuda / Patrimonio2.16
Ratio corriente1.43
Piotroski F-Score6
Altman Z-Score-4.63

Ratios Clave (10 años)

Año2016201720182019202020212022202320242025
P/E-2.89-8.40-3.76-2.68-1.11-1.53-0.99-4.43-5.76-77.40
P/VC5.765.421.021.901.575.0720.17-7.60-8.1512.70
P/V255.793.633.112.231.321.770.361.192.501.75
Margen Bruto-7443.0%99.7%96.3%56.6%78.3%61.5%92.3%61.9%60.6%83.3%
Margen Operativo-8889.9%-44.9%-85.8%-85.5%-128.2%-125.0%-27.6%-23.8%-31.5%9.9%
Margen Neto-8843.5%-43.2%-82.7%-83.5%-130.6%-133.3%-32.2%-26.7%-43.3%-2.3%

Empresas relacionadas: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA

Explorar sector: Healthcare · Biotechnology

Más secciones de AKBA: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos

Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones